In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at firstname.lastname@example.org to determine how to proceed.
IMPORTANT NOTICE: ID-CGD Sponsored Testing Program
Please let this serve as a courtesy notification that GeneDx will no longer be accepting test orders for the ID-CGD Program after October 6, 2023.
Upcoming important dates:
All GeneDx Genetic Test Reports resulting from test orders submitted via the ID-CGD Program that are received on or before October 6, 2023 will continue to be issued as usual, per the reporting preference(s) listed on the ID-CGD Test Requisition Form, and within the normal turnaround time for GeneDx Test Code T989 (approx. 3 weeks).
Testing for any orders submitted via the ID-CGD Program that are received after October 6, 2023 will be placed on hold. Our GeneDx clinical team will reach out to discuss testing options. Of note: it will remain possible to order GeneDx Test Code T989 via alternate billing options.
If you should have any questions regarding previous test orders already submitted via the ID-CGD Program (or test orders that you intend to submit via the ID-CGD Program on or before October 6, 2023), please continue to reach out to the BioPharma team here at GeneDx via email@example.com.
If you should have any further questions regarding the continuation of the ID-CGD Program, please reach out to your Horizon Clinical Science Associate (CSA) or visit CGDPathways.com to connect with a Horizon CSA.
If you should have any questions regarding available tests here at GeneDx, please reach out to our Client Support team via firstname.lastname@example.org to be connected to your local GeneDx Sales Representative and/or Client Relations Manager.